<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="caac70034" xml:lang="en" article-type="other" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CA Cancer J Clin</journal-id><journal-id journal-id-type="iso-abbrev">CA Cancer J Clin</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CAAC</journal-id><journal-title-group><journal-title>Ca</journal-title></journal-title-group><issn pub-type="ppub">0007-9235</issn><issn pub-type="epub">1542-4863</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12788344</article-id><article-id pub-id-type="pmcid-ver">PMC12788344.1</article-id><article-id pub-id-type="pmcaid">12788344</article-id><article-id pub-id-type="pmcaiid">12788344</article-id><article-id pub-id-type="pmid">40991533</article-id><article-id pub-id-type="doi">10.3322/caac.70034</article-id><article-id pub-id-type="publisher-id">CAAC70034</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Virtual Tumor Board</subject></subj-group><subj-group subj-group-type="heading"><subject>Virtual Tumor Board</subject></subj-group></article-categories><title-group><article-title>A patient with newly diagnosed breast cancer found to have mosaic <italic toggle="yes">TP53</italic> likely pathogenic variant</article-title><alt-title alt-title-type="right-running-head">Mosaic <italic toggle="yes">TP53</italic> pathogenic variant in breast cancer</alt-title></title-group><contrib-group><contrib id="caac70034-cr-0001" contrib-type="author"><name name-style="western"><surname>Mistry</surname><given-names initials="HD">Hetal D.</given-names></name><degrees>MD</degrees><xref rid="caac70034-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="caac70034-cr-0002" contrib-type="author"><name name-style="western"><surname>Adams</surname><given-names initials="MR">MacKenzie R.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-3293-243X</contrib-id><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="caac70034-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="caac70034-cr-0003" contrib-type="author"><name name-style="western"><surname>Taneja</surname><given-names initials="C">Charu</given-names></name><degrees>MD</degrees><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="caac70034-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="caac70034-cr-0004" contrib-type="author"><name name-style="western"><surname>Massingham</surname><given-names initials="LJ">Lauren J.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2497-1552</contrib-id><xref rid="caac70034-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="caac70034-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="caac70034-cr-0005" contrib-type="author"><name name-style="western"><surname>Dibble</surname><given-names initials="EH">Elizabeth H.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3906-6272</contrib-id><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="caac70034-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="caac70034-cr-0006" contrib-type="author"><name name-style="western"><surname>Leonard</surname><given-names initials="KL">Kara L.</given-names></name><degrees>MD, MS</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7953-4205</contrib-id><xref rid="caac70034-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="caac70034-cr-0007" contrib-type="author"><name name-style="western"><surname>Hart</surname><given-names initials="J">Jesse</given-names></name><degrees>DO</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4169-2854</contrib-id><xref rid="caac70034-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="caac70034-cr-0008" contrib-type="author"><name name-style="western"><surname>Lagos</surname><given-names initials="GG">Galina G.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-6151-6545</contrib-id><xref rid="caac70034-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="caac70034-cr-0009" contrib-type="author" corresp="yes"><name name-style="western"><surname>Fenton</surname><given-names initials="MA">Mary Anne</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6467-5352</contrib-id><xref rid="caac70034-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="caac70034-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>mfenton@brownhealth.org</email></address></contrib></contrib-group><aff id="caac70034-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Hematology/Oncology</named-content>
<institution>Brown University Health Cancer Institute</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="caac70034-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Warren Alpert School of Medicine</institution>
<institution>Brown University</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><aff id="caac70034-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Brown University Health</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><aff id="caac70034-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Surgery</named-content>
<institution>Brown University Health</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><aff id="caac70034-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Division of Genetics and Genomics</named-content>
<named-content content-type="organisation-division">Boston Children's Hospital</named-content>
<institution>Department of Pediatrics, Harvard Medical School</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="caac70034-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Brown University Health</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><aff id="caac70034-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Radiation Oncology</named-content>
<institution>Brown University Health</institution>
<institution>Warren Alpert Medical School of Brown University</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="caac70034-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine</named-content>
<institution>Brown University Health</institution>
<institution>Rhode Island Hospital</institution>
<institution>Warren Alpert School of Medicine</institution>
<institution>Brown University</institution>
<city>Providence</city>
<named-content content-type="country-part">Rhode Island</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mary Anne Fenton, Department of Hematology/Oncology, Brown University Health Cancer Institute and Warren Alpert School of Medicine, 222 Richmond Street, Providence, RI 02903, USA.<break/>
Email: <email>mfenton@brownhealth.org</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2026</year></pub-date><volume>76</volume><issue seq="20">1</issue><issue-id pub-id-type="pmc-issue-id">504674</issue-id><issue-id pub-id-type="doi">10.3322/caac.v76.1</issue-id><elocation-id>e70034</elocation-id><history><date date-type="rev-recd"><day>25</day><month>7</month><year>2025</year></date><date date-type="received"><day>30</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-10 00:25:12.930"><day>10</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAAC-76-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAAC-76-0.pdf"/><counts><fig-count count="4"/><table-count count="0"/><page-count count="12"/><word-count count="10171"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January/February 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:09.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="caac70034-cit-0085"><string-name name-style="western"><surname>Mistry</surname><given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Taneja</surname><given-names>C</given-names></string-name>, et al. <article-title>A patient with newly diagnosed breast cancer found to have mosaic <italic toggle="yes">TP53</italic> likely pathogenic variant</article-title>. <source>CA Cancer J Clin</source>. <year>2026</year>;<elocation-id>e70034</elocation-id>. doi:<pub-id pub-id-type="doi">10.3322/caac.70034</pub-id><pub-id pub-id-type="pmcid">PMC12788344</pub-id><pub-id pub-id-type="pmid">40991533</pub-id></mixed-citation>
</p></notes></front><body id="caac70034-body-0001"><sec id="caac70034-sec-0010"><title>CASE OVERVIEW</title><p>A 36&#8208;year&#8208;old, nulligravid woman with a history of controlled eosinophilic esophagitis, asthma, and dense fibrocystic breasts was referred to the Breast Health Center after abnormal screening mammography. She reported recent fatigue and intermittent diarrhea but had a negative colonoscopy and food allergy testing this year.</p><p>Her family history was significant for a maternal grandmother with a question of uterine cancer, a maternal grandfather who died of renal cancer at age 62 years, a paternal grandmother who died of brain cancer at age 56 years, a paternal grandfather who died of brain cancer at age 80 years, and a history of premalignant changes in the esophagus in her father. She has never smoked tobacco and consumes zero to three drinks of alcohol weekly. She has been physically active in multiple sports, including biking and swimming, and played the cello.</p><p>Mammography demonstrated extremely dense breast tissue with new calcifications in both breasts. Diagnostic mammography demonstrated indeterminate grouped calcifications spanning 19 mm in the right breast at 5 o'clock and 7 mm in the left breast 12 o'clock. She subsequently underwent stereotactic needle biopsies of both areas, which revealed right breast ductal carcinoma in situ (DCIS), nuclear grade 3, with 90% estrogen receptor (ER) expression; and left ductal carcinoma, nuclear grade 3, with 95% ER expression, 40% progesterone receptor (PR) expression, negative human epidermal growth factor receptor 2 (HER&#8208;2) status, and a Ki&#8208;67 index of 40%. Within the left breast biopsy there was an absence of myoepithelial cells, raising concern that the findings reflected an unusual type of invasive carcinoma. She then underwent bilateral breast magnetic resonance imaging (MRI), which revealed the known areas of DCIS in the bilateral breasts and also revealed a 1.0&#8208;cm mass inferior to the left breast DCIS at 12 o'clock that was considered suspicious. On subsequent ultrasound, it corresponded to an 8&#8208;mm mass in the left breast at 10 o'clock. A biopsy of the mass demonstrated a spindle cell tumor, favoring malignant phyllodes tumor with pleomorphic liposarcomatous differentiation that was negative for ER, PR, and HER2 (triple&#8208;negative), with a Ki&#8208;67 index of 30%.</p><p>At her multidisciplinary consultation, she was referred for genetic evaluation having met National Comprehensive Cancer Network (NCCN) criteria based on her diagnosis of breast cancer when younger than 50 years.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Given the concern for invasive left breast cancer and possible need for chemotherapy, she was also referred for fertility preservation.</p><p>She completed a comprehensive 76&#8208;gene germline genetic test, which revealed tumor protein p53 (<italic toggle="yes">TP53)</italic> likely pathogenic variant (LPV; c.716A&gt;G; p.N239S). Pathogenic variants (PVs) and LPVs are DNA sequence changes that are associated with increased risk of disease. There is well established evidence that PVs are disease&#8208;causing, and LPVs are strongly suspected but have less definitive evidence. Both are considered <italic toggle="yes">positive</italic> results in genetic testing indicating a diagnostic result.</p><p>When <italic toggle="yes">TP53</italic> PVs/LPVs are identified in a comprehensive germline panel, this raises concern for Li&#8211;Fraumeni syndrome (LFS). However, delineation of the origin of the <italic toggle="yes">TP53</italic> PV/LPV is necessary because detection of the <italic toggle="yes">TP53</italic> PV/LPV can occur through multiple mechanisms, including clonal hematopoiesis of indeterminate potential (CHIP), mosaicism, or a true germline finding.</p><p>She elected to proceed with bilateral skin and nipple&#8208;sparing mastectomy with left axillary sentinel lymph node (SLN) biopsy (SLNB) and Magtrace injection (Endomag; A Hologic Company) into the right breast for delayed SLNB. Neurotization of flaps was performed with a nerve graft from the fourth and fifth intercostal nerves to the nipple&#8211;areolar complex and placement of prepectoral tissue expanders. She recovered well after surgery, and the final pathology revealed right breast DCIS, no residual left breast DCIS, and a malignant phyllodes tumor excised to negative margins. Left SLNB was negative, and axillary lymph node dissection was not required.</p></sec><sec id="caac70034-sec-0020"><title>MULTIDISCIPLINARY DISCUSSION</title><sec id="caac70034-sec-0030"><title>Pathology</title><p>Initial biopsies demonstrated bilateral high&#8208;grade DCIS, both of which were ER&#8208;positive (90%&#8211;95%; strong). A separate biopsy of a left breast mass revealed a malignant fibroepithelial lesion containing a benign epithelial component and a high&#8208;grade malignant spindle cell component with lipoblastic differentiation. The spindle cell component was positive for CD34 and SMA (smooth muscle actin) and was negative for numerous cytokeratin stains and p63. Moreover, fluorescence in situ hybridization analysis was negative for amplification of MDNW (mouse double minute 2 homolog), excluding a dedifferentiated liposarcoma. Bilateral mastectomies were performed, and 22 mm of DCIS was found in the right breast, whereas the left breast contained a small (5.6 mm) malignant phyllodes tumor with lipoblastic differentiation; no residual DCIS was identified in the left breast (Figure&#160;<xref rid="caac70034-fig-0001" ref-type="fig">1</xref>, Figure&#160;<xref rid="caac70034-fig-0002" ref-type="fig">2</xref>, and Figure&#160;<xref rid="caac70034-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="caac70034-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>The left breast mass biopsy contained a fibroepithelial lesion with overtly malignant, high&#8208;grade spindle cells and a benign epithelial component. Lipoblastic differentiation is present in the bottom right of the biopsy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAAC-76-0-g003.jpg"/></fig><fig position="float" fig-type="FIGURE" id="caac70034-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>The left mastectomy specimen contained a small (5.6 mm), malignant phyllodes tumor with lipoblastic differentiation, which was remote from ductal carcinoma in situ.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CAAC-76-0-g002.jpg"/></fig><fig position="float" fig-type="FIGURE" id="caac70034-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Numerous ducts containing high&#8208;grade ductal carcinoma in situ, solid pattern, were identified in the right mastectomy specimen.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CAAC-76-0-g004.jpg"/></fig></sec><sec id="caac70034-sec-0040"><title>Radiology</title><p>Several years before presentation, the patient was diagnosed with a large left breast cyst and underwent excision. After that, she was recommended by her gynecologist to undergo annual mammographic screening alternating with whole&#8208;breast ultrasound in the setting of fibrocystic changes and dense breasts. Thus the patient began annual mammography screening before age 40 years and had four prior normal mammograms, with normal imaging 1 year before diagnosis. Of note, she did not undergo high&#8208;risk MRI screening, which would have been recommended annually starting at ages 25&#8211;30 years had her high&#8208;risk status been known.<xref rid="caac70034-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> In patients with a new diagnosis of breast cancer, contrast&#8208;enhanced breast MRI is appropriate to evaluate for locoregional disease and can accurately assess tumor size and detect additional cancers in the ipsilateral or contralateral breast.<xref rid="caac70034-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>The screening guidelines for breast disease depend on risk, and high&#8208;risk includes patients with genetic&#8208;based increased risk, those with a calculated lifetime risk of breast cancer &#8805;20%, and those exposed to chest radiation at young ages. Patients with genetic&#8208;based increased risk of breast cancer, annual breast MRI is recommended.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> If performed, such patients can delay mammographic screening until age 40 years rather than starting earlier than those with average risk. All women should undergo breast cancer risk assessment by age 25 years so that those at high risk can be identified and appropriate screening can be initiated earlier than age 40 years when appropriate.<xref rid="caac70034-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Her mammogram showed new calcifications in both breasts (Figure&#160;<xref rid="caac70034-fig-0004" ref-type="fig">4</xref>) and dense breast tissue, which limits the sensitivity of mammography.<xref rid="caac70034-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="caac70034-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>(A) Right and (B)&#160;left mediolateral oblique screening mammogram images and (C)&#160;right and (D)&#160;left craniocaudal screening mammogram images show extremely dense breast tissue and grouped calcifications in the right breast at 5 o'clock, posterior depth, and in the left breast at 12 o'clock, posterior depth (arrows). (E)&#160;Right craniocaudal magnification view also shows the right breast calcifications, which measure up to 7 mm (arrow). (F)&#160;Left craniocaudal magnification view also show the left breast calcifications, which measure up to 19 mm (arrow). Bilateral stereotactic biopsies with clip placement were performed. (G)&#160;Maximum&#8208;intensity projection image from a subsequent contrast&#8208;enhanced MRI shows minimal enhancement at the biopsy sites and a separate, 1.0&#8208;cm, irregular, enhancing mass in the left breast at 10 o'clock far posterior depth (arrow), which had suspicious washout enhancement kinetics. (H)&#160;A subsequent MRI&#8208;directed, targeted ultrasound showed a 0.8&#8208;cm mass at 10 o'clock, posterior depth, corresponding to the MRI finding (arrow). Ultrasound&#8208;guided biopsy with clip placement was performed. Subsequent whole&#8208;body MRI was performed without contrast and revealed no other suspicious findings. MRI indicates magnetic resonance imaging.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="CAAC-76-0-g001.jpg"/></fig></sec><sec id="caac70034-sec-0050"><title>Genetics</title><p>Approximately 5%&#8211;10% of breast cancers can be attributed to high&#8208;penetrance hereditary breast cancer genes.<xref rid="caac70034-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> With scientific advancements, multigene panels are now being used regularly and have resulted in even higher yields. Diagnostic yield across studies of multigene panels can be variable; a larger study of 3845 individuals with breast cancer produced a yield of 15.7% using a 30&#8208;gene panel.<xref rid="caac70034-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Additional factors, such as significant family history of cancer, triple&#8208;negative breast cancer, or early onset breast cancer, may increase diagnostic yield even further.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="caac70034-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> For example, in two different studies, multigene panel testing in premenopausal patients with breast cancer resulted in yields of 23% and 42.5%.<xref rid="caac70034-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="caac70034-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> In addition to germline <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> PV/LPV, germline <italic toggle="yes">TP53</italic> LPV/PV is a common cause of early onset breast cancer. Genetic evaluation and testing are important components of the initial work&#8208;up for early onset breast cancer because the results can affect treatment recommendations. Individuals diagnosed with a germline heterozygous <italic toggle="yes">TP53</italic> PV/LPV have LFS.</p><p>LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma. Of note, differences in the types of variants can affect cancer risk assessment. For example, missense variants that have a dominant&#8208;negative effect have a higher cancer risk, and these variants are often more penetrant in childhood. Loss&#8208;of&#8208;function variants or missense variants with a nondominant&#8208;negative effect are predominantly found in families with mostly adult cancers.<xref rid="caac70034-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> An LFS diagnosis in an individual with newly diagnosed breast cancer includes consideration of bilateral mastectomy, as opposed to breast&#8208;conserving surgery, which is practice&#8208;changing. This is because of the risk of secondary malignancies and an effort to mitigate that risk (and reduce the need for adjuvant radiotherapy, which can be associated with radiation&#8208;induced secondary malignancy).<xref rid="caac70034-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Surveillance recommendations for those diagnosed with LFS are intensive, thus it is important to apply them to those truly diagnosed with LFS and at increased risk for cancer, as in this patient.</p><p>Germline genetic testing, typically in the form of multigene panels using next&#8208;generation sequencing, is typically performed on blood, saliva, or buccal samples because the DNA isolated from these sample is typically considered representative of the germline.<xref rid="caac70034-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> However, in the case of <italic toggle="yes">TP53</italic>, interpretation of next&#8208;generation sequencing results can be very challenging because the testing could be representative of a true germline result (i.e., present in all cells in the body) but also could be secondary to a mosaicism, clonal hematopoiesis, or neoplastic in origin (corresponding to circulating tumor DNA that can be observed in individuals with metastatic cancers).</p><p>The term mosaicism originates from <italic toggle="yes">mosaic</italic>, referring to an intricate piece that is created from small segments of material pieced together that appears to be a collective image at a distance, but on close assessment, contains distinguishably different individual components. In the field of medical genetics, constitutional mosaicism is defined as the existence of genetically distinct populations of cells originating during embryogenesis in an individual. It is caused by a de novo (acquired) change in the DNA during embryogenesis resulting in additional cell line(s) in an individual. The de novo change is carried on among all of that cell&#8217;s progeny cells going forward. Of note, de novo changes in DNA are not uncommon; in fact, we know that there are 1&#160;&#215;&#160;10<sup>&#8722;8</sup> sequencing changes per generation, giving rise to 45&#8211;60 de novo variants per person.<xref rid="caac70034-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> These 45&#8211;60 variants are not always associated with disease as the variants for many reasons (i.e., benign or likely benign variant, located in a noncoding region of the DNA, resulting in a heterozygous change [carrier] in a recessive gene). To give some more visual examples of a mosaic condition, mosaic (segmental) neurofibromatosis type 1 or McCune&#8211;Albright syndrome are two examples in which there are detectable skin findings in limited areas of the body. Other examples include <italic toggle="yes">PIK3CA</italic>&#8208;related overgrowth syndromes (which can result in focal or segmental overgrowth) or mosaic Turner syndrome, in which the individual can have milder features (taller stature than classic Turner syndrome and even some preserved ovarian function to experience puberty and some fertility). Typically, in a clinical genetics practice, if an individual is has a de novo disease&#8208;causing variant identified (for example, in an autosomal&#8208;dominant condition), part of the counseling around this PV/LPV is that there is a slightly increased recurrence risk (typically 1%&#8211;5% recurrence risk in future pregnancies) because of the risk for gonadal mosaicism, which is mosaicism isolated to the gonadal ovary or teste tissue.<xref rid="caac70034-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> This 1%&#8211;5% recurrence risk, although low, is still much higher compared with the general population's risk of the disease (each disease has its own associated population risk, but, generally, most conditions have a population risk well below 1%). There is no way to identify concern for a mosaic hereditary cancer predisposition syndrome until a cancer is detected because these conditions are typically nonsyndromic (i.e., without features on physical examination). Once it is detected, however, in addition to conferring an increased risk in the individual&#8217;s own tissue(s) that harbor the PV/LPV and considering increased surveillance, it is also important to counsel that it may also confer a risk of transmission to offspring if the gonadal tissue harbors the affected gene.<xref rid="caac70034-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="caac70034-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>It has been determined that clonal hematopoiesis is causative of a blood/saliva next&#8208;generation sequencing result in 25%&#8211;38.8% of cases.<xref rid="caac70034-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="caac70034-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> CHIP is the result of expansion of mutant hematopoietic stem and progenitor cells and is associated with increased risk for hematologic neoplasm (such as myelodysplastic syndromes and acute myeloid leukemia). The <italic toggle="yes">TP53</italic> gene is one of the most common genes associated with CHIP. The frequency of CHIP increases with age, tobacco use, and exposure to chemotherapy or radiotherapy.<xref rid="caac70034-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Once an individual has a <italic toggle="yes">TP53</italic> PV/LPV detected in a blood/saliva/buccal sample, it is essential to distinguish between germline PVs/LPVs, mosaic PVs/LPVs, clonal hematopoiesis, and circulating tumor DNA secondary to malignancy. Germline and mosaic <italic toggle="yes">TP53</italic> PVs/LPVs are considered LFS and require surveillance and cascade testing. Clonal hematopoiesis and circulating tumor DNA secondary to malignancy do not confer an increased risk for LFS or other tumors and thus do not require the intensive surveillance needed for LFS; however, they require their own surveillance based on these findings. There are multiple mechanisms that can be used to clarify the source of the <italic toggle="yes">TP53</italic> PV/LPV detected. Cascade testing of parents and/or siblings can clarify because, if a family member also harbors the <italic toggle="yes">TP53</italic> PV/LPV, then germline origin is confirmed. In addition, alternative DNA sources without mononuclear cells, such as skin biopsy, can be considered.<xref rid="caac70034-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> If a skin biopsy sample of noncancerous cells results in the detection of a <italic toggle="yes">TP53</italic> PV/LPV, then the germline is confirmed. If the skin biopsy is negative for the <italic toggle="yes">TP53</italic> PV/LPV, then clonal hematopoiesis or malignancy should be considered.</p><p>In addition to determining risk for the individual patient, a germline <italic toggle="yes">TP53</italic> PV/LPV has a cascading effect for other family members. The testing of at&#8208;risk family members can result in their own diagnosis of LFS, and surveillance can be initiated, which aids in earlier cancer diagnoses and thus better outcomes.</p><p>This result can also be effective if the individual is considering procreation. It provides an opportunity to consider reproductive options, such as in vitro fertilization with preimplantation genetic diagnosis. Preimplantation genetic diagnosis involves using in vitro fertilization techniques to form embryos; then, by using a few cells from an early embryo, testing for the known <italic toggle="yes">TP53</italic> PV/LPV can be completed.<xref rid="caac70034-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Unaffected embryos can be chosen for implantation, thus eliminating the risk of passing on the affected gene and resulting offspring that are not affected with LFS.</p><sec id="caac70034-sec-0060"><title>Returning to our case</title><p>The patient had a comprehensive 76&#8208;gene germline genetic test with a concerning <italic toggle="yes">TP53</italic> LPV. This is not yet a diagnostic result; however, given the concern for LFS, whole&#8208;body MRI and cascade testing for family members were completed concurrently:<list list-type="bullet"><list-item><p>Whole&#8208;body MRI scan was recommended per NCCN guidelines given the possibility of other primary cancers in a patient with concern for LFS. Whole&#8208;body MRI was notable for bilateral breast lesions and cystic lesions within the pelvis, including an indeterminate lesion measuring up to 3.3 cm. There was no other evidence of malignancy. Pelvic ultrasound showed an anterior fundal pedunculated fibroid measuring 5.5&#160;&#215;&#160;3.4&#160;&#215;&#160;4.5 cm and a second posterior fundal fibroid measuring 2.6&#160;&#215;&#160;2.6&#160;&#215;&#160;2.6 cm.</p></list-item><list-item><p>Cascade testing of the patient&#8217;s family members (parents) was completed because it is a simple and relatively quick way to confirm a germline <italic toggle="yes">TP53</italic> LPV. If either of her parents was confirmed to harbor the <italic toggle="yes">TP53</italic> LPV, her diagnosis of LFS would be confirmed because she inherited the <italic toggle="yes">TP53</italic> LPV from that parent germline. Parental testing was completed, and a diagnosis of LFS was not confirmed with this testing because the results were negative in both parents.</p></list-item></list>
</p><p>Given the negative parental testing, an alternative way to confirm an LFS diagnosis is to confirm the finding in an unaffected (noncancerous) tissue. If the <italic toggle="yes">TP53</italic> LPV is detected in another unaffected tissue, this would be diagnostic for LFS because it would confirm a germline finding or mosaicism (noncancerous cells affected with the predisposition), both of which are treated as LFS. The most common way to complete this is by skin biopsy. A skin biopsy was completed on the posterior shoulder, which also was negative for the <italic toggle="yes">TP53</italic> LPV.</p><p>Notable extra data for this patient were available because she was concurrently going through the process of in vitro fertilization and preimplantation genetic diagnosis. Given the concern for LFS in the patient and the known specific <italic toggle="yes">TP53</italic> LPV, testing of the embryos was possible. Forty&#8208;four eggs were retrieved. One of the arrested embryos tested positive for the known maternal <italic toggle="yes">TP53</italic> LPV. The 43 negative eggs and negative parental test results were reassuring findings for the potential offspring and her parents; however, given her early onset diagnoses of bilateral DCIS and phyllodes tumor and one embryo with the <italic toggle="yes">TP53</italic> LPV, there was still much higher suspicion for mosaicism over CHIP as the explanation for the patient&#8217;s <italic toggle="yes">TP53</italic> LPV. Thus our hypothesis was that the patient had germline mosaicism; and, if that were true, then molecular testing of the three breast tumors would indicate that all harbor (in some capacity) the exact same <italic toggle="yes">TP53</italic> LPV. Because we all harbor billions of base pairs in our genome, if the patient was not mosaic, then each of the three tumors would have unique molecular pathogenic variants because the chance of each of the three tumors harboring the same specific variant sporadically is infinitesimally small. To prove that each tumor harbored the same genomic alteration, somatic testing was completed for all three tumors. The same specific <italic toggle="yes">TP53</italic> LPV (c.716A&gt;G [p.N239S]) was detected in all three tumors.</p><p>Genetic testing of the tumor cells may identify somatic, germline, or mosaic DNA alterations. The variant allele frequency (VAF) is an extra piece of information that is reported on tumor testing. The VAF represents the percentage of the cells within the sample that harbor the particular variant of interest. Typically, it can be helpful in the consideration of tumor clonality in somatic tumor testing, but it can also provide insights into potential germline findings. A high VAF (&gt;30%) is suggestive of a germline alteration because a germline alteration for a dominant condition should have an allele frequency of 50% (50% of the alleles are the reference allele, and 50% harbor the genomic alteration [PV/LPV]).<xref rid="caac70034-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="caac70034-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> A caveat when considering VAF includes that there can be a great amount of variation in this prediction, and it is not a validated method for determining germline status, but it can be a helpful clue that should be a red flag indication to order a germline test. Differing from how the testing is typically used, in this case, we sought to use the somatic VAF to provide evidence in consideration of mosaicism given the germline finding. In our patient, the VAF for the <italic toggle="yes">TP53</italic> c.716A&gt;G in each lesion was as follows: left breast DCIS, 2.4%; right breast DCIS, 33.9%; and left phyllodes tumor, 60.8%. The presence of the same genomic alteration in each tumor points toward the presence of this variant in that particular tissue. If the somatic testing was completed before the germline test, the high VAF in the right breast DCIS and the left phyllodes tumor should have triggered the completion of a germline test. The evidence of the somatic molecular testing and the embryos is consistent with mosaicism in our patient and is diagnostic for LFS. Thus she will complete the standard surveillance for LFS going forward. Her parents are unaffected with LFS and thus do not need surveillance. The chance of siblings being affected is small because this appears to be postzygotic mosaicism, but it is reasonable to complete the cascade testing for her siblings to ensure that this is true. The ovary tissue does appear to be at least partially affected given the embryo data. The patient is in the process of determining whether she would like to proceed with family planning using in vitro fertilization with a preimplantation genetic diagnosis in the hope of obtaining a viable, unaffected embryo for implantation.</p></sec></sec><sec id="caac70034-sec-0070"><title>Surgery</title><p>DCIS accounts for 20%&#8211;30% of newly diagnosed breast cancer, and the mainstay of treatment is surgery. The recurrence rate is approximately 12% for low&#8208;risk patients, rising to 27% in high&#8208;risk patients over 10 years, with a breast cancer&#8208;specific survival rate of 98% at 10 years regardless of the type of breast surgery.<xref rid="caac70034-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Surgery is recommended for DCIS because of the risk of upgrade to invasive cancer upon excision and the risk of progression to invasive cancer. However, which patients with DCIS will progress to invasive cancer is not well understood. There is an interest in identifying a subset of patients for whom active surveillance may be reasonable. Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program demonstrate that the risk of ipsilateral cancer is 1%&#8211;2% per year with active surveillance for DCIS.<xref rid="caac70034-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Ongoing clinical trials, such as COMET (ClinicalTrials.gov identifier NCT02926911), LORIS (International Standard Randomized Controlled Trial Number ISRCTN27544578), LORD (ClinicalTrials.gov identifier NCT02492607), and LORETTA (University Hospital Medical Information Network identifier UMIN000028298), all have similar eligibility criteria and are evaluating this prospectively for patients with low&#8208;risk DCIS.<xref rid="caac70034-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> We did not believe our patient was a candidate for active surveillance because of her young age, high&#8208;grade tumor, bilateral breast cancer, and concurrent malignant phyllodes tumor.</p><p>The breast cancer risk for women with LFS/germline <italic toggle="yes">TP53</italic> LPVs/PVs is 80%&#8211;90%,<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> with most breast cancers occurring at a younger age. These cancers are also associated with higher rates of ipsilateral breast cancer with breast&#8208;conserving surgery, higher rates of contralateral breast cancer, and lower rates of relapse&#8208;free and overall survival in individuals who have LFS&#8208;related breast cancer compared with other individuals who have breast cancer. Furthermore, malignant phyllodes breast tumors in women are associated with LFS.<xref rid="caac70034-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The risk of a second cancer within 10 years of diagnosis is as high as 50%,<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> leading to the recommendation for risk&#8208;reducing mastectomy in these patients. Typically, radiation is recommended after surgery for DCIS and decreases the risk of local recurrence by 50%&#8211;70%. The Radiation Therapy Oncology Group study RTOG 9804 randomized patients with low&#8208;risk DCIS to lumpectomy with or without radiation and observed that the risk of local recurrence at 14 years was 7.1% after radiation and 15.1% without radiation (hazard ratio, 0.36; <italic toggle="yes">p</italic>&#160;=&#160;.007), and the risk of invasive locoregional disease was 5.4% and 9.5%, respectively (hazard ratio, 0.44; <italic toggle="yes">p</italic>&#160;=&#160;.27).<xref rid="caac70034-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> However, our patient did not meet criteria for low&#8208;risk DCIS (grade 3, young age), and radiation is not recommended in patients with LFS because of their susceptibility to radiation&#8208;induced cancers. Mastectomy is recommended rather than lumpectomy with radiation.<xref rid="caac70034-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>It has been demonstrated that preservation of the nipple&#8211;areola complex at the time of skin&#8208;sparing mastectomy with immediate reconstruction is safe from an oncologic perspective,<xref rid="caac70034-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> although there is a loss of sensation after mastectomy, and the return of sensation can be unpredictable. In a study by Peled et&#160;al. evaluating patient&#8208;reported satisfaction with their implant&#8208;based reconstruction using the BREAST&#8208;Q questionnaire, the mean nipple satisfaction score regarding nipple appearance was 89% at 1 year; however, 40% were satisfied with nipple sensation.<xref rid="caac70034-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> This gained national attention with the publication of an article in <italic toggle="yes">The New York Times</italic> addressing loss of sensation in the reconstructed breast and the lack of education regarding this.<xref rid="caac70034-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> The sensory nerves to the nipple course through the breast parenchyma and are transected during mastectomy, affecting the patient&#8217;s ability to experience protective sensation and sensual touch. In a study by Casaubon et&#160;al., patients undergoing mastectomy had a decreased persistence of breast intimacy (42.9% vs. 65.4%) and loss of pleasurable breast caress (20% vs. 66.2%) compared with those undergoing lumpectomy.<xref rid="caac70034-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>The role of neurotization is to restore this function as well as to minimize chronic pain in the reconstructed breast, which is reported in 25%&#8211;60% of women.<xref rid="caac70034-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> This has been enhanced by our understanding of the sensory nerve supply of the breast. A cadaver study by Knackstedt et&#160;al. in 2019 demonstrated the predictable location of the sensory nerves and allowed for the identification of a suitable target for nerve grafting. The lateral intercostal nerve can be reliably identified near the fourth rib, within 2 cm of the pectoralis margin.<xref rid="caac70034-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> A meta&#8208;analysis by Smeele et&#160;al. identified the anterior cutaneous branch and lateral cutaneous branch of the fourth intercostal nerve as suppliers of the largest surface area of the breast skin and nipple/nipple&#8211;areola complex. The lateral cutaneous branch of the fourth intercostal nerve is the most consistent contributory nerve to the nipple/nipple&#8211;areola complex (pooled prevalence, 89.0%; 95% confidence interval [CI], 0.80%&#8211;0.94%).<xref rid="caac70034-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>The return of sensation has been well studied in autologous reconstruction,<xref rid="caac70034-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> but Djohan et&#160;al. and Peled and Peled<xref rid="caac70034-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="caac70034-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> were among the first to describe the use of a processed nerve&#8208;interposition allograft between the lateral fourth intercostal nerve and the nipple&#8211;areola complex. In their studies of women undergoing mastectomy with implant&#8208;based reconstruction and careful nerve preservation and grafting, there was an 80%&#8211;90% rate of preserved function.<xref rid="caac70034-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="caac70034-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Djohan et&#160;al. demonstrated improvements in skin and nipple sensation, but with decreased sensation compared with preoperative testing.<xref rid="caac70034-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> There is an increasing awareness of the technical considerations that would allow for successful neurotization,<xref rid="caac70034-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> which results in improved recovery of sensation and increases patient satisfaction.</p><p>SLNB is recommended for patients with DCIS who are undergoing mastectomy.<xref rid="caac70034-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="caac70034-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> In a study from The University of Texas MD Anderson Cancer Center, among 398 patients undergoing surgery for DCIS, microinvasive or invasive cancer was identified in 20% and was more likely to occur in younger patients, those with high&#8208;grade DCIS, those with a DCIS size &gt;4 cm, and those who had DCIS diagnosed on core biopsy. The predictor of a positive lymph node in patients with DCIS was the presence of a palpable mass.<xref rid="caac70034-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> In a further study from The University of Texas MD Anderson Cancer Center, of 1234 patients undergoing mastectomy with SLNB for DCIS, there was an upgrade to microinvasive or invasive cancer in 26.5%, and 10.7% of patients had positive SLNs. Of these patients, 5.4% had isolated tumor cells in the SLN; 2.9% had micrometastasis, and 2.4% had macrometastasis. The presence of occult invasion on core biopsy, diagnosis by excisional biopsy, DCIS measuring &gt;2 cm, papillary histology, and multiple interventions before SLNB were associated with positive SLNB in that study.<xref rid="caac70034-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Similarly, in single&#8208;center studies of patients undergoing surgery for DCIS, DCIS was upstaged to invasive cancer in 19.2%&#8211;42% of patients, and only 2.7%&#8211;4.4% of patients undergoing mastectomy for DCIS had a positive SLN.<xref rid="caac70034-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="caac70034-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="caac70034-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="caac70034-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> In view of the low rate of SLN positivity, there is consideration to forgo SLNB if it would not change the recommendations for adjuvant treatment. Studies evaluating the morbidity associated with the performance of a SLNB cite a 4% risk of lymphedema, a 13% risk of sensory neuropathy, and a 3% risk of motor neuropathy.<xref rid="caac70034-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> Other side effects include arm and shoulder pain (25.8%), numbness (12.0%), paresthesias (6.4%), lymphedema (7.1%), axillary web syndrome (8%), loss of strength (26.2%), and limitations in range of motion (19.5%). Approximately 38% of these patients were treated by a physical therapist concerning the experienced complaints after SLNB.<xref rid="caac70034-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> In the ALMANC trial (Axillary Lymphatic Mapping Against Nodal Axillary Clearance), the reported lymphedema rate was 5%, and the rate of sensory loss was 11%.<xref rid="caac70034-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Similarly, in the National Surgical Adjuvant Breast and Bowel Project (NSABP)&#8208;B32 trial, the rate of arm volume changes with SLNB at 36 months was 8%, and numbness and tingling at 6 months were reported by 15% and 10%, respectively.<xref rid="caac70034-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> In a study using Surveillance, Epidemiology, and End Results data, Killelea et&#160;al. demonstrated that 16.8% of women who underwent SLNB had complications from this procedure compared with 11.3% of those who did not undergo SLNB (<italic toggle="yes">p</italic>&#160;&lt;&#160;.001).<xref rid="caac70034-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> SLNB use was significantly associated with the incidence of any complication (adjusted odds ratio [AOR], 1.39; 99% CI, 1.18&#8211;1.63), lymphedema (AOR, 4.45; 99% CI, 2.27&#8211;8.75), wound infection (AOR, 1.24; 99% CI, 1.00&#8211;1.54), seroma (AOR, 1.40; 99% CI, 1.03&#8211;1.91), and pain (AOR, 1.31; 99% CI, 1.04&#8211;1.65). This morbidity is not insignificant in view of the overall low rate of lymph node positivity observed in these patients.</p><p>It has been demonstrated that the use of superparamagnetic iron oxide (SPIO) is noninferior for identification of the SLN node compared with using the standard radioisotope with or without blue dye.<xref rid="caac70034-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="caac70034-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="caac70034-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> The SentiNot trial introduced the concept of <italic toggle="yes">delayed SLNB</italic>, defined as marking an SLN with a tracer and removal of the SLN at a future date if medically indicated.<xref rid="caac70034-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
</p><p>In this procedure, SPIO is injected into the breast parenchyma at the time of the primary breast surgery for DCIS; if invasive cancer was identified upon breast excision, SLNB was performed later (hence, the term <italic toggle="yes">delayed</italic>); typically, SLN biopsy was performed within a median of 28 days from the primary surgery, using concurrent injection of technetium&#8208;99m (<sup>99m</sup>Tc) and blue dye on the day of SLNB. The SentiNot trial (ClinicalTrials.gov identifier NCT04722692)&#160;included patients with DCIS undergoing mastectomy, with DCIS grade 2 measuring &gt;2 cm, with any size grade 3 DCIS, or with any mass&#8208;forming DCIS. In patients with invasive breast cancer who subsequently underwent SLNB, <sup>99m</sup>Tc was administered to analyze the detection rate of SLN with SPIO and <sup>99m</sup>Tc. The SLN detection rate with SPIO was higher than that with <sup>99m</sup>Tc (without blue dye; 92.7% vs. 50.9%; <italic toggle="yes">p</italic>&#160;&lt;&#160;.001) and had a higher number of nodes detected (86.9 vs. 32.3; <italic toggle="yes">p</italic>&#160;&lt;&#160;.001). Almost 80% of patients in this study were able to avoid SLNB because they had pure DCIS or were older than 70 years with an ER&#8208;positive, 6&#8208;mm, invasive ductal breast cancer or microinvasion on final pathology because SLN would not alter management, and the resulting cost reduction was 28.1%. These results have been confirmed in other studies as well.<xref rid="caac70034-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="caac70034-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="caac70034-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Thus, for patients undergoing mastectomy for DCIS or a genetic predisposition, using a delayed SLNB technique could spare 84.6% patients from the procedure and subsequent morbidity and cost.</p></sec><sec id="caac70034-sec-0080"><title>Radiation oncology</title><p>Radiation therapy plays an important role in breast&#8208;conservation therapy for DCIS and invasive breast cancer. As noted above, breast&#8208;conserving surgery for DCIS is typically offered as initial management. If surgery is pursued, adjuvant therapy for DCIS typically involves radiation and/or hormone therapy. Four randomized clinical trials (NSABP B&#8208;17; European Organization for Research and Treatment of Cancer trial EORTC 10853; the United Kingdom, Australia, and New Zealand DCIS trial [ISRCTN99513870]; and this study SweDCIS trial was governed by the Swedish Breast Cancer Group (SweBCG)) have demonstrated a benefit of adjuvant radiation therapy in combination with lumpectomy versus lumpectomy alone.<xref rid="caac70034-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="caac70034-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="caac70034-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>, <xref rid="caac70034-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="caac70034-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> Multiple studies have also demonstrated that adjuvant radiation after lumpectomy reduces the risk of local recurrence by approximately 50% for both invasive and noninvasive breast cancer. Despite this, studies have demonstrated no measurable effect on breast cancer&#8208;specific or all&#8208;cause mortality in these populations.<xref rid="caac70034-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> Therefore, although radiation effectively reduces recurrence, it is essential to balance its benefit against the potential long&#8208;term side effects of radiotherapy. For phyllodes tumor, radiation therapy is also considered for adjuvant treatment after resection in certain patients to reduce the risk of in&#8208;breast recurrence of this tumor.</p><p>In vitro studies suggest that <italic toggle="yes">TP53</italic> PVs/LPVs are associated with increased radiosensitivity. It has been demonstrated that patients with LFS who receive radiation therapy have an increased risk of radiation&#8208;related malignancies within irradiated areas. The reported risk of developing radiation&#8208;induced malignancy ranges from 15% to 35% in the modern literature.<xref rid="caac70034-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>, <xref rid="caac70034-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="caac70034-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> For this reason, alternative therapies that might avoid the use of radiation therapy are recommended in the treatment of LFS&#8208;related malignancies.</p><p>In our patient, the diagnosis of LFS led to a change in recommendation for the management of her DCIS and phyllodes tumor. After the detection of a mosaic <italic toggle="yes">TP53</italic> LPV diagnostic for LFS, bilateral mastectomy was recommended, and she was able to avoid radiotherapy.</p></sec><sec id="caac70034-sec-0090"><title>Medical oncology</title><sec id="caac70034-sec-0100"><title>Ductal carcinoma in situ</title><p>DCIS is a noninvasive breast cancer characterized by heterogeneous pathologic and physiologic features. Pathologically, DCIS is recognized as a precursor to invasive breast cancer, which occurs when malignant epithelial cells escape containment of the mammary duct basement membrane and infiltrate the stroma. DCIS accounts for 25% of all newly diagnosed breast cancers, and approximately 35% of cases are diagnosed with screening mammography in asymptomatic women.<xref rid="caac70034-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="caac70034-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>, <xref rid="caac70034-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> Fortunately, only one in from six to 10 cases of DCIS progress to invasive breast cancer, and the prognosis is overall excellent.<xref rid="caac70034-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> Advancements in management have focused on a multidisciplinary approach that has allowed for the de&#8208;escalation of treatment to decrease treatment toxicities while also reducing breast cancer recurrence.</p><p>In terms of medical management, adjuvant hormone therapy with the use of selective ER modulators and aromatase inhibitors plays a role in chemoprevention for both invasive breast cancer and DCIS, because greater than two thirds of all DCIS cases express the ER protein. Several randomized clinical trials have tested adjuvant hormone therapy among women who underwent breast&#8208;conservation surgery with and without radiation. The NSABP B&#8208;24 trial investigated adjuvant treatment with tamoxifen for 5 years. At 6 years' follow&#8208;up, tamoxifen led to a 37% reduction in all new breast cancer events compared with placebo. Post&#8208;hoc analysis indicated that this improvement was limited to ER&#8208;positive DCIS.<xref rid="caac70034-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="caac70034-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> This trial highlighted that endocrine therapy should be considered for patients with hormone receptor&#8208;positive DCIS. Although data from the NSABP B&#8208;24 trial identified a notable reduction in breast cancer events with hormone therapy, additional studies have demonstrated mixed findings. In a National Health Service cohort, the adjusted HR for death did not support endocrine therapy, which supports the perspective that hormone therapy for DCIS might play a role in prevention and not adjuvant therapy.<xref rid="caac70034-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>
</p></sec></sec><sec id="caac70034-sec-0110"><title>Phyllodes tumor</title><p>Phyllodes tumors are fibroepithelial breast tumors that account for &lt;1% of breast neoplasms.<xref rid="caac70034-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> Clinically, these tumors present as rapidly enlarging, painless, well defined breast masses. Histologically, they are classified as benign, borderline, or malignant. Malignant phyllodes tumors account for only one quarter of cases. To qualify as malignant, the tumor must have marked stromal atypia, stromal overgrowth, &#8805;10 mitoses per high&#8208;power field, increased stromal cellularity, and infiltrative borders. Alternatively, the presence of heterologous elements that can resemble chondrosarcoma, osteosarcoma, liposarcoma, or rhabdomyosarcoma also qualify as malignant phyllodes tumors. Necrosis, stromal overgrowth, and the presence of heterologous elements are associated with increased risk of recurrence and decreased overall survival.<xref rid="caac70034-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>
</p><p>The preferred management for phyllodes tumor is surgical excision. Benign and borderline phyllodes tumors can be cured with surgery alone based on a low risk of recurrence. Local excision or lumpectomy is acceptable for benign phyllodes tumors. Mastectomy reduces the risk of local recurrence and improves disease free survival for borderline and malignant phyllodes tumors, although wide local excision with negative margins is also an acceptable approach.<xref rid="caac70034-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Positive margins are associated with increased recurrence in malignant phyllodes tumor, and re&#8208;excision is advised. Axillary lymphadenectomy is not indicated because of the low risk of lymph node involvement.<xref rid="caac70034-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> There is controversary regarding the role of adjuvant radiation for malignant phyllodes tumor. It may reduce the risk of local recurrence, particularly in the presence of close margins, but does not prolong overall survival.<xref rid="caac70034-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>, <xref rid="caac70034-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> Adjuvant chemotherapy is not used in standard practice because of a lack of clinical benefit.<xref rid="caac70034-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> For metastatic disease, there are limited effective systemic therapy options, so optimal locoregional control is imperative.<xref rid="caac70034-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>
</p><p>Phyllodes tumors have been associated with germline <italic toggle="yes">TP53</italic>, <italic toggle="yes">BRCA1</italic>, and <italic toggle="yes">RB1</italic> PVs/LPVs. In a cohort of patients with phyllodes tumors who underwent germline genetic testing for <italic toggle="yes">TP53</italic>, 9.5% had a PV/LPV, which can affect management, specifically with avoidance of radiation.<xref rid="caac70034-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> PV/LPV rates can be higher in malignant phyllodes tumor, and genetic evaluation should be considered. In our patient, genetic testing was pursued given early breast cancer onset, leading to identification of the<italic toggle="yes">TP53</italic> LPV. Based on the presence of pleomorphic liposarcomatous differentiation in her breast biopsy, her tumor was classified as a malignant phyllodes tumor. It was appropriately managed using mastectomy with negative margins. Given her mosaic <italic toggle="yes">TP53</italic> LPV, which is diagnostic for LFS, radiation was not offered, and she will be monitored with surveillance.</p></sec><sec id="caac70034-sec-0120"><title>LFS/<italic toggle="yes">TP53</italic> surveillance</title><p>As mentioned above, LFS is associated with increased risk of developing various malignancies, including breast, skin and soft tissue, brain, gastrointestinal, lung, prostate, and thyroid tumors, as well as leukemia and lymphoma.<xref rid="caac70034-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>, <xref rid="caac70034-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> Given this predilection for cancer in both children and adults, screening has become the standard of care with the advancement and implementation of surveillance protocols.<xref rid="caac70034-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>, <xref rid="caac70034-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>
</p><p>All patients with LFS should have a comprehensive physical examination (including a neurologic examination) every 6&#8211;12 months as part of routine surveillance.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Breast cancer awareness and screening should begin by age 18 years, with periodic and consistent breast self&#8208;examinations for patients with LFS. This should be followed by clinical breast examinations every 6&#8211;12 months starting at age 20 years. Imaging modalities for surveillance include annual screening breast MRI for women between ages 20 and 75 years. For patients with LFS who are older than 75 years, management of screenings should be considered on an individual basis. Mammograms can be considered if MRI is unavailable; however, the avoidance of increased radiation exposure associated with mammograms is recommended. In addition, discussion of risk&#8208;reducing bilateral mastectomy is suggested in this population.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Gastric and colon cancer surveillance includes a screening upper endoscopy and colonoscopy every 2&#8211;5 years starting at age 25 years. Pancreatic cancer screenings should start at age 50 years with annual contrast&#8208;enhanced MRI/magnetic resonance cholangiopancreatography and/or endoscopic ultrasound.<xref rid="caac70034-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> Adrenocortical carcinoma surveillance should continue until at least age 40 years. Dermatologic examinations should begin annually at age 18 years. Blood testing, including complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase, should also take place every 3&#8211;4 months to screen for leukemia and lymphoma.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Given the increased risk for sarcoma and the overall increased risk for malignancies across organ types, annual whole&#8208;body MRI studies are recognized as an integral component of routine surveillance.<xref rid="caac70034-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> Annual brain MRI should also be considered given the risk for central nervous system malignancies. If whole&#8208;body MRI is unavailable, an alternative comprehensive imaging of the entire body is recommended.<xref rid="caac70034-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="caac70034-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref>, <xref rid="caac70034-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>
</p><p>There are additional specific recommendations for men and in the pediatric population, which will not be discussed here. Moreover, it should be noted that surveillance recommendations may vary based on individual and familial history of malignancy; therefore, this must be taken into account and screenings must be adjusted accordingly. In addition, the psychosocial and quality&#8208;of&#8208;life effects of this daunting diagnosis should be addressed throughout each patient&#8217;s journey.</p><p>In conclusion, the implementation of comprehensive surveillance strategies is vital and complex for individuals who have LFS, with the objectives of facilitating early detection of malignancies and improving survival outcomes.</p></sec><sec id="caac70034-sec-0130"><title>Current clinical status</title><p>She is now considering the possibility of in vitro fertilization, which may entail additional rounds of egg harvesting for preimplantation testing for <italic toggle="yes">TP53</italic> LPVs in her offspring. There is no indication for adjuvant therapy or chemoprevention in a patient after bilateral mastectomies and DCIS.</p></sec><sec id="caac70034-sec-0140"><title>Patient perspective</title><p>Having had dense, fibrocystic tissue and no idea about my high&#8208;risk genetic status beforehand, I was lucky to have been referred for breast imaging prior to the recommended age guidelines. I had no inclination that I had breast cancer, nor that I was predisposed to it and to many other sorts of cancers. My medical team was proactive in getting additional information through subsequent testing to help guide their recommendations for surgery and other cancer treatment options. My genetic results shifted the conversation from conservation of breast tissue to prevention of risks associated with radiation exposure. This made it easier to accept the reality of a bilateral mastectomy as something positive and adjusted my focus instead to identifying my priorities for reconstruction&#8212;seeking prepectoral placement of silicone implants to avoid additional tissue damage and strength reduction while also attempting breast reinnervation for sensation preservation. Genetic results affected my consideration of family planning, too&#8212;with the mosaic <italic toggle="yes">TP53</italic> LPV, there are implications for both me and my potential children; and, the earlier one can know, the better to make informed decisions. We opted to create embryos to test them for the <italic toggle="yes">TP53</italic> LPV. Although the findings have largely been inconclusive, at least the issue is known. Had my own genetic testing been performed earlier, regular scans also could have begun sooner and would not have left detecting my cancer early somewhat up to chance. With no additional treatment currently needed postsurgery, heightened vigilance with routine evaluations and scans now offer some comfort as I go back to living my life.</p></sec></sec><sec id="caac70034-sec-0150"><title>CONCLUSION</title><p>In young patients, it is critical to carefully obtain a history and assess for genetic risk factors for malignancy. Point&#8208;of&#8208;care multigene hereditary cancer testing provides essential genetic information in patients with newly diagnosed breast cancer before medical or surgical interventions, which can significantly alter management recommendations. This case highlights the importance of involving multiple subspecialties in the care of patients who have breast cancer and the utility of genetics expertise as one of those subspecialties. Careful evaluation of genetic testing results was a critical component of this genetic assessment because of the complexity of this case. This case highlights that, when a <italic toggle="yes">TP53</italic> PV/LPV is detected through germline testing, it is essential to determine the origin of that result before making any medical decisions based on the result. The management recommendations for LFS compared with CHIP are drastically different. This case was particularly interesting because the issue was not as simple as determining that the <italic toggle="yes">TP53</italic> LPV was germline by cascade testing of the parents, as is often the case. It required careful consideration of the aspects of the case and recognition of the significance of three primary breast cancers in a woman aged 36 years with a <italic toggle="yes">TP53</italic> LPV, negative parental testing, and a negative skin biopsy that remained concerning for a mosaic condition. This case required thinking <italic toggle="yes">outside of the box</italic> to continue the assessment of different tissue samples, to ultimately confirm mosaic LFS, and to recognize that the best chance of confirming multiple affected areas was testing all three breast cancers. Of note, using the tumor samples to determine multiple tumors with the same <italic toggle="yes">TP53</italic> LPV to confirm the diagnosis was even <italic toggle="yes">outside of the box</italic> for the tumor testing laboratory; in fact, testing was cancelled by the laboratory multiple times and was designated <italic toggle="yes">not indicated</italic>. Through perseverance and multiple phone calls explaining the rationale for the testing, the laboratory finally completed the somatic tumor testing for all three samples, which was ultimately successful in confirmation of LFS. In conclusion, careful assessment and multidisciplinary discussion of varying types of breast tumors (benign vs. malignant), with thoughtful and persistent assessment of concerning genetic findings to confirm a diagnosis, allowed for streamlined decision making and drastically changed the clinical management and future surveillance recommendations with a goal of primary prevention of secondary malignancies for this patient.</p></sec><sec sec-type="COI-statement" id="caac70034-sec-0160"><title>CONFLICT OF INTEREST STATEMENT</title><p>Kara L. Leonard reports royalties from Springer Publication outside the submitted work. Mary Anne Fenton reports grants/contracts from Pfizer and support for other professional activities from Elsevier and MJH Life Sciences outside the submitted work. The remaining authors disclosed no conflicts of interest.</p></sec></body><back><ref-list content-type="cited-references" id="caac70034-bibl-0001"><title>REFERENCES</title><ref id="caac70034-bib-0001"><label>1</label><mixed-citation publication-type="book" id="caac70034-cit-0001"><collab collab-type="authors">National Comprehensive Cancer Network Cancer&#174; (NCCN&#174;)</collab>
. <source>Genetic/Familial High&#8208;Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) Version 1.2025</source>. <publisher-name>NCCN</publisher-name>; <year>2024</year>. Accessed July 10, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=2%26id=1545" ext-link-type="uri">https://www.nccn.org/guidelines/guidelines&#8208;detail?category=2&amp;id=1545</ext-link></mixed-citation></ref><ref id="caac70034-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="caac70034-cit-0002"><string-name name-style="western"><surname>Monticciolo</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Newell</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Moy</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Destounis</surname><given-names>SV</given-names></string-name>. <article-title>Breast cancer screening for women at higher&#8208;than&#8208;average risk: updated recommendations from the ACR</article-title>. <source>J Am Coll Radiol</source>. <year>2023</year>;<volume>20</volume>(<issue>9</issue>):<fpage>902</fpage>&#8208;<lpage>914</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacr.2023.04.002</pub-id><pub-id pub-id-type="pmid">37150275</pub-id></mixed-citation></ref><ref id="caac70034-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="caac70034-cit-0003"><collab collab-type="authors">Expert Panel on Breast Imaging</collab>
; <string-name name-style="western"><surname>McDonald</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Scheel</surname><given-names>JR</given-names></string-name>, et&#160;al. <article-title>ACR Appropriateness Criteria&#174; imaging of invasive breast cancer</article-title>. <source>J Am Coll Radiol</source>. <year>2024</year>;<volume>21</volume>(<issue>6S</issue>):<fpage>S168</fpage>&#8208;<lpage>S202</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacr.2024.02.021</pub-id><pub-id pub-id-type="pmid">38823943</pub-id></mixed-citation></ref><ref id="caac70034-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="caac70034-cit-0004"><string-name name-style="western"><surname>Kolb</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Lichy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Newhouse</surname><given-names>JH</given-names></string-name>. <article-title>Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations</article-title>. <source>Radiology</source>. <year>2002</year>;<volume>225</volume>(<issue>1</issue>):<fpage>165</fpage>&#8208;<lpage>175</lpage>. doi:<pub-id pub-id-type="doi">10.1148/radiol.2251011667</pub-id><pub-id pub-id-type="pmid">12355001</pub-id></mixed-citation></ref><ref id="caac70034-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="caac70034-cit-0005"><string-name name-style="western"><surname>Nagy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sweet</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Eng</surname><given-names>C</given-names></string-name>. <article-title>Highly penetrant hereditary cancer syndromes</article-title>. <source>Oncogene</source>. <year>2004</year>;<volume>23</volume>(<issue>38</issue>):<fpage>6445</fpage>&#8208;<lpage>6470</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.onc.1207714</pub-id><pub-id pub-id-type="pmid">15322516</pub-id></mixed-citation></ref><ref id="caac70034-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="caac70034-cit-0006"><string-name name-style="western"><surname>Neben</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Stedden</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Multi&#8208;gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines</article-title>. <source>J Mol Diagn</source>. <year>2019</year>;<volume>21</volume>(<issue>4</issue>):<fpage>646</fpage>&#8208;<lpage>657</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmoldx.2019.03.001</pub-id><pub-id pub-id-type="pmid">31201024</pub-id></mixed-citation></ref><ref id="caac70034-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="caac70034-cit-0007"><string-name name-style="western"><surname>Catana</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Apostu</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Antemie</surname><given-names>RG</given-names></string-name>. <article-title>Multi gene panel testing for hereditary breast cancer&#8212;is it ready to be used?</article-title><source>Med Pharm Rep</source>. <year>2019</year>;<volume>92</volume>(<issue>3</issue>):<fpage>220</fpage>&#8208;<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.15386/mpr-1083</pub-id><pub-id pub-id-type="pmid">31460501</pub-id><pub-id pub-id-type="pmcid">PMC6709965</pub-id></mixed-citation></ref><ref id="caac70034-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="caac70034-cit-0008"><string-name name-style="western"><surname>Rummel</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Lovejoy</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shriver</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Ellsworth</surname><given-names>RE</given-names></string-name>. <article-title>Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>2017</year>;<volume>164</volume>(<issue>3</issue>):<fpage>593</fpage>&#8208;<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-017-4291-8</pub-id><pub-id pub-id-type="pmid">28503720</pub-id></mixed-citation></ref><ref id="caac70034-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="caac70034-cit-0009"><string-name name-style="western"><surname>Zografos</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Andrikopoulou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Papatheodoridi</surname><given-names>AM</given-names></string-name>, et&#160;al. <article-title>Multi&#8208;gene mutation profiling by targeted next&#8208;generation sequencing in premenopausal breast cancer</article-title>. <source>Genes (Basel)</source>. <year>2022</year>;<volume>13</volume>(<issue>8</issue>):<elocation-id>1362</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/genes13081362</pub-id><pub-id pub-id-type="pmid">36011273</pub-id><pub-id pub-id-type="pmcid">PMC9407588</pub-id></mixed-citation></ref><ref id="caac70034-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="caac70034-cit-0010"><string-name name-style="western"><surname>Evans</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Woodward</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Bajalica&#8208;Lagercrantz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Frebourg</surname><given-names>T</given-names></string-name>. <article-title>Germline TP53 testing in breast cancers: why, when and how?</article-title><source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>12</issue>):<elocation-id>3762</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cancers12123762</pub-id><pub-id pub-id-type="pmid">33327514</pub-id><pub-id pub-id-type="pmcid">PMC7764913</pub-id></mixed-citation></ref><ref id="caac70034-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="caac70034-cit-0011"><string-name name-style="western"><surname>Blondeaux</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Arecco</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Punie</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Germline TP53 pathogenic variants and breast cancer: a narrative review</article-title>. <source>Cancer Treat Rev</source>. <year>2023</year>;<volume>114</volume>:<elocation-id>102522</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102522</pub-id><pub-id pub-id-type="pmid">36739824</pub-id></mixed-citation></ref><ref id="caac70034-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="caac70034-cit-0012"><string-name name-style="western"><surname>Weitzel</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Chao</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Nehoray</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Somatic TP53 variants frequently confound germ&#8208;line testing results</article-title>. <source>Genet Med</source>. <year>2018</year>;<volume>20</volume>(<issue>8</issue>):<fpage>809</fpage>&#8208;<lpage>816</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gim.2017.196</pub-id><pub-id pub-id-type="pmid">29189820</pub-id><pub-id pub-id-type="pmcid">PMC5976505</pub-id></mixed-citation></ref><ref id="caac70034-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="caac70034-cit-0013"><string-name name-style="western"><surname>Mohiuddin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kooy</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>CE</given-names></string-name>. <article-title>De novo mutations, genetic mosaicism and human disease</article-title>. <source>Front Genet</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>983668</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fgene.2022.983668</pub-id><pub-id pub-id-type="pmid">36226191</pub-id><pub-id pub-id-type="pmcid">PMC9550265</pub-id></mixed-citation></ref><ref id="caac70034-bib-0014"><label>14</label><mixed-citation publication-type="data" id="caac70034-cit-0014"><string-name name-style="western"><surname>Neuser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Popp</surname><given-names>D</given-names></string-name>, et&#160;al. <data-title>The refined recurrence risk of de novo variants due to parental mosaicism [preprint]</data-title>. <source>medRxiv</source>. <year>2025</year>. doi:<pub-id pub-id-type="doi">10.1101/2025.07.02.25330538</pub-id></mixed-citation></ref><ref id="caac70034-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="caac70034-cit-0015"><string-name name-style="western"><surname>Behjati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Maschietto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>RD</given-names></string-name>, et&#160;al. <article-title>A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>5</issue>):<elocation-id>e96531</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0096531</pub-id><pub-id pub-id-type="pmid">24810334</pub-id><pub-id pub-id-type="pmcid">PMC4014518</pub-id></mixed-citation></ref><ref id="caac70034-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="caac70034-cit-0016"><string-name name-style="western"><surname>Kovar</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Auinger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jug</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pillwein</surname><given-names>K</given-names></string-name>. <article-title>p53 mosaicism with an exon 8 germline mutation in the founder of a cancer&#8208;prone pedigree</article-title>. <source>Oncogene</source>. <year>1992</year>;<volume>7</volume>(<issue>11</issue>):<fpage>2169</fpage>&#8208;<lpage>2173</lpage>.<pub-id pub-id-type="pmid">1359493</pub-id></mixed-citation></ref><ref id="caac70034-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="caac70034-cit-0017"><string-name name-style="western"><surname>Coffee</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Kidd</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel</article-title>. <source>Cancer Genet</source>. <year>2017</year>;<volume>211</volume>:<fpage>5</fpage>&#8208;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cancergen.2017.01.002</pub-id><pub-id pub-id-type="pmid">28279308</pub-id></mixed-citation></ref><ref id="caac70034-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="caac70034-cit-0018"><string-name name-style="western"><surname>Frebourg</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bajalica Lagercrantz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Magenheim</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DG</given-names></string-name>. <article-title>Guidelines for the Li&#8211;Fraumeni and heritable TP53&#8208;related cancer syndromes</article-title>. <source>Eur J Hum Genet</source>. <year>2020</year>;<volume>28</volume>(<issue>10</issue>):<fpage>1379</fpage>&#8208;<lpage>1386</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41431-020-0638-4</pub-id><pub-id pub-id-type="pmid">32457520</pub-id><pub-id pub-id-type="pmcid">PMC7609280</pub-id></mixed-citation></ref><ref id="caac70034-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="caac70034-cit-0019"><collab collab-type="authors">Preimplantation genetic testing: ACOG committee opinion</collab>
, <article-title>number 799</article-title>. <source>Obstet Gynecol</source>. <year>2020</year>;<volume>135</volume>(<issue>3</issue>):<fpage>e133</fpage>&#8208;<lpage>e137</lpage>. doi:<pub-id pub-id-type="doi">10.1097/AOG.0000000000003714</pub-id><pub-id pub-id-type="pmid">32080053</pub-id></mixed-citation></ref><ref id="caac70034-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="caac70034-cit-0020"><string-name name-style="western"><surname>DeLeonardis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cannistra</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Rangachari</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tung</surname><given-names>N</given-names></string-name>. <article-title>When should tumor genomic profiling prompt consideration of germline testing?</article-title><source>J Oncol Pract</source>. <year>2019</year>;<volume>15</volume>(<issue>9</issue>):<fpage>465</fpage>&#8208;<lpage>473</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jop.19.00201</pub-id><pub-id pub-id-type="pmid">31509718</pub-id></mixed-citation></ref><ref id="caac70034-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="caac70034-cit-0021"><string-name name-style="western"><surname>Kraft</surname><given-names>IL</given-names></string-name>, <string-name name-style="western"><surname>Godley</surname><given-names>LA</given-names></string-name>. <article-title>Identifying potential germline variants from sequencing hematopoietic malignancies</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>. <year>2020</year>;<volume>2020</volume>(<issue>1</issue>):<fpage>219</fpage>&#8208;<lpage>227</lpage>. doi:<pub-id pub-id-type="doi">10.1182/hematology.2020006910</pub-id><pub-id pub-id-type="pmid">33275754</pub-id><pub-id pub-id-type="pmcid">PMC7727528</pub-id></mixed-citation></ref><ref id="caac70034-bib-0022"><label>22</label><mixed-citation publication-type="book" id="caac70034-cit-0022"><string-name name-style="western"><surname>Hwang</surname><given-names>ES</given-names></string-name>. <source>Ductal carcinoma in situ updates and future directions</source>. <publisher-name>2024 Miami Breast Cancer Conference</publisher-name>. Presented March 9, 2024.</mixed-citation></ref><ref id="caac70034-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="caac70034-cit-0023"><string-name name-style="western"><surname>Ryser</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Cancer outcomes in DCIS patients without locoregional treatment</article-title>. <source>J Natl Cancer Inst</source>. <year>2019</year>;<volume>111</volume>(<issue>9</issue>):<fpage>952</fpage>&#8208;<lpage>960</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djy220</pub-id><pub-id pub-id-type="pmid">30759222</pub-id><pub-id pub-id-type="pmcid">PMC6748726</pub-id></mixed-citation></ref><ref id="caac70034-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="caac70034-cit-0024"><string-name name-style="western"><surname>Hwang</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Hyslop</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lynch</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low&#8208;risk ductal carcinoma in situ (DCIS)</article-title>. <source>BMJ Open</source>. <year>2019</year>;<volume>9</volume>(<issue>3</issue>):<elocation-id>e026797</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2018-026797</pub-id><pub-id pub-id-type="pmcid">PMC6429899</pub-id><pub-id pub-id-type="pmid">30862637</pub-id></mixed-citation></ref><ref id="caac70034-bib-0025"><label>25</label><mixed-citation publication-type="book" id="caac70034-cit-0025"><string-name name-style="western"><surname>Schneider</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zelley</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nichols</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Garber</surname><given-names>J</given-names></string-name>. <part-title>Li&#8211;Fraumeni syndrome</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Adam</surname><given-names>MP</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Feldman</surname><given-names>J</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Mirzaa</surname><given-names>GM</given-names></string-name></person-group>, eds. <source>GeneReviews&#174; [Internet]. University of Washington, Seattle</source>; <year>1993</year>. Accessed July 10, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1311/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK1311/</ext-link></mixed-citation></ref><ref id="caac70034-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="caac70034-cit-0026"><string-name name-style="western"><surname>McCormick</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Woodward</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Randomized phase III trial evaluating radiation following surgical excision for good&#8208;risk ductal carcinoma in situ: long&#8208;term report from NRG Oncology/RTOG 9804</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>32</issue>):<fpage>3574</fpage>&#8208;<lpage>3582</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.21.01083</pub-id><pub-id pub-id-type="pmid">34406870</pub-id><pub-id pub-id-type="pmcid">PMC8577682</pub-id></mixed-citation></ref><ref id="caac70034-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="caac70034-cit-0027"><string-name name-style="western"><surname>Gosangi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dixe de Oliveira Santo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Keraliya</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Li&#8211;Fraumeni syndrome: imaging features and guidelines</article-title>. <source>Radiographics</source>. <year>2024</year>;<volume>44</volume>(<issue>8</issue>):<elocation-id>e230202</elocation-id>. doi:<pub-id pub-id-type="doi">10.1148/rg.230202</pub-id><pub-id pub-id-type="pmid">39024172</pub-id></mixed-citation></ref><ref id="caac70034-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="caac70034-cit-0028"><string-name name-style="western"><surname>Galimberti</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vicini</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Corso</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Nipple&#8208;sparing and skin&#8208;sparing mastectomy: review of aims, oncological safety and contraindications</article-title>. <source>Breast</source>. <year>2017</year>;<volume>34</volume>(<issue>suppl 1</issue>):<fpage>S82</fpage>&#8208;<lpage>S84</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.breast.2017.06.034</pub-id><pub-id pub-id-type="pmid">28673535</pub-id><pub-id pub-id-type="pmcid">PMC5837802</pub-id></mixed-citation></ref><ref id="caac70034-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="caac70034-cit-0029"><string-name name-style="western"><surname>Peled</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Duralde</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Foster</surname><given-names>RD</given-names></string-name>, et&#160;al. <article-title>Patient&#8208;reported outcomes and satisfaction after total skin&#8208;sparing mastectomy and immediate expander&#8208;implant reconstruction</article-title>. <source>Ann Plast Surg</source>. <year>2014</year>;<volume>72</volume>(<issue>suppl 1</issue>):<fpage>S48</fpage>&#8208;<lpage>S52</lpage>. doi:<pub-id pub-id-type="doi">10.1097/sap.0000000000000020</pub-id><pub-id pub-id-type="pmid">24317238</pub-id></mixed-citation></ref><ref id="caac70034-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="caac70034-cit-0030"><string-name name-style="western"><surname>Rabin</surname><given-names>RC</given-names></string-name>. <article-title>After mastectomies, an unexpected blow: numb new breasts</article-title>. <source>The New York Times</source>; January 29, <year>2017</year>.</mixed-citation></ref><ref id="caac70034-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="caac70034-cit-0031"><string-name name-style="western"><surname>Casaubon</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Kuehn</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Pesek</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Breast&#8208;specific sensuality and appearance satisfaction: comparison of breast&#8208;conserving surgery and nipple&#8208;sparing mastectomy</article-title>. <source>J Am Coll Surg</source>. <year>2020</year>;<volume>230</volume>(<issue>6</issue>):<fpage>990</fpage>&#8208;<lpage>998</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2020.02.048</pub-id><pub-id pub-id-type="pmid">32272205</pub-id></mixed-citation></ref><ref id="caac70034-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="caac70034-cit-0032"><string-name name-style="western"><surname>Gfrerer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sager</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Ford</surname><given-names>OA</given-names></string-name>, et&#160;al. <article-title>Targeted nipple areola complex reinnervation: technical considerations and surgical efficiency in implant&#8208;based breast reconstruction</article-title>. <source>Plast Reconstr Surg Glob Open</source>. <year>2022</year>;<volume>10</volume>(<issue>7</issue>):<elocation-id>e4420</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/gox.0000000000004420</pub-id><pub-id pub-id-type="pmid">35923997</pub-id><pub-id pub-id-type="pmcid">PMC9325332</pub-id></mixed-citation></ref><ref id="caac70034-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="caac70034-cit-0033"><string-name name-style="western"><surname>Knackstedt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gatherwright</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cakmakoglu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Djohan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Djohan</surname><given-names>R</given-names></string-name>. <article-title>Predictable location of breast sensory nerves for breast reinnervation</article-title>. <source>Plast Reconstr Surg</source>. <year>2019</year>;<volume>143</volume>(<issue>2</issue>):<fpage>393</fpage>&#8208;<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.1097/prs.0000000000005199</pub-id><pub-id pub-id-type="pmid">30489501</pub-id></mixed-citation></ref><ref id="caac70034-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="caac70034-cit-0034"><string-name name-style="western"><surname>Smeele</surname><given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Bijkerk</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>van Kuijk</surname><given-names>SMJ</given-names></string-name>, <string-name name-style="western"><surname>Lataster</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>van der Hulst</surname><given-names>RRWJ</given-names></string-name>, <string-name name-style="western"><surname>Tuinder</surname><given-names>SMH</given-names></string-name>. <article-title>Innervation of the female breast and nipple: a systematic review and meta&#8208;analysis of anatomical dissection studies</article-title>. <source>Plast Reconstr Surg</source>. <year>2022</year>;<volume>150</volume>(<issue>2</issue>):<fpage>243</fpage>&#8208;<lpage>255</lpage>. doi:<pub-id pub-id-type="doi">10.1097/prs.0000000000009306</pub-id><pub-id pub-id-type="pmid">35652898</pub-id></mixed-citation></ref><ref id="caac70034-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="caac70034-cit-0035"><string-name name-style="western"><surname>Beugels</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cornelissen</surname><given-names>AJM</given-names></string-name>, <string-name name-style="western"><surname>Spiegel</surname><given-names>AJ</given-names></string-name>, et&#160;al. <article-title>Sensory recovery of the breast after innervated and non&#8208;innervated autologous breast reconstructions: a systematic review</article-title>. <source>J Plast Reconstr Aesthet Surg</source>. <year>2017</year>;<volume>70</volume>(<issue>9</issue>):<fpage>1229</fpage>&#8208;<lpage>1241</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bjps.2017.05.001</pub-id><pub-id pub-id-type="pmid">28687258</pub-id></mixed-citation></ref><ref id="caac70034-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="caac70034-cit-0036"><string-name name-style="western"><surname>Djohan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Scomacao</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Knackstedt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cakmakoglu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Grobmyer</surname><given-names>SR</given-names></string-name>. <article-title>Neurotization of the nipple&#8211;areola complex during implant&#8208;based reconstruction: evaluation of early sensation recovery</article-title>. <source>Plast Reconstr Surg</source>. <year>2020</year>;<volume>146</volume>(<issue>2</issue>):<fpage>250</fpage>&#8208;<lpage>254</lpage>. doi:<pub-id pub-id-type="doi">10.1097/prs.0000000000006976</pub-id><pub-id pub-id-type="pmid">32740571</pub-id></mixed-citation></ref><ref id="caac70034-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="caac70034-cit-0037"><string-name name-style="western"><surname>Peled</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Peled</surname><given-names>ZM</given-names></string-name>. <article-title>Nerve preservation and allografting for sensory innervation following immediate implant breast reconstruction</article-title>. <source>Plast Reconstr Surg Glob Open</source>. <year>2019</year>;<volume>7</volume>(<issue>7</issue>):<elocation-id>e2332</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/gox.0000000000002332</pub-id><pub-id pub-id-type="pmid">31942359</pub-id><pub-id pub-id-type="pmcid">PMC6952160</pub-id></mixed-citation></ref><ref id="caac70034-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="caac70034-cit-0038"><string-name name-style="western"><surname>Peled</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>von Eyben</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Peled</surname><given-names>ZM</given-names></string-name>. <article-title>Sensory outcomes after neurotization in nipple&#8208;sparing mastectomy and implant&#8208;based breast reconstruction</article-title>. <source>Plast Reconstr Surg Glob Open</source>. <year>2023</year>;<volume>11</volume>(<issue>12</issue>):<elocation-id>e5437</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/gox.0000000000005437</pub-id><pub-id pub-id-type="pmid">38074501</pub-id><pub-id pub-id-type="pmcid">PMC10703124</pub-id></mixed-citation></ref><ref id="caac70034-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="caac70034-cit-0039"><string-name name-style="western"><surname>Coopey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Keleher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Daniele</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Careful where you cut: strategies for successful nerve&#8208;preserving mastectomy</article-title>. <source>Plast Reconstr Surg Glob Open</source>. <year>2024</year>;<volume>12</volume>(<issue>5</issue>):<elocation-id>e5817</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/gox.0000000000005817</pub-id><pub-id pub-id-type="pmid">38752216</pub-id><pub-id pub-id-type="pmcid">PMC11095964</pub-id></mixed-citation></ref><ref id="caac70034-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="caac70034-cit-0040"><string-name name-style="western"><surname>Brackstone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baldassarre</surname><given-names>FG</given-names></string-name>, <string-name name-style="western"><surname>Perera</surname><given-names>FE</given-names></string-name>, et&#160;al. <article-title>Management of the axilla in early&#8208;stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>27</issue>):<fpage>3056</fpage>&#8208;<lpage>3082</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.21.00934</pub-id><pub-id pub-id-type="pmid">34279999</pub-id></mixed-citation></ref><ref id="caac70034-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="caac70034-cit-0041"><string-name name-style="western"><surname>Lyman</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Somerfield</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Bosserman</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Perkins</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Giuliano</surname><given-names>AE</given-names></string-name>. <article-title>Sentinel lymph node biopsy for patients with early&#8208;stage breast cancer: American Society of Clinical Oncology clinical practice guideline update</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>5</issue>):<fpage>561</fpage>&#8208;<lpage>564</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2016.71.0947</pub-id><pub-id pub-id-type="pmid">27937089</pub-id></mixed-citation></ref><ref id="caac70034-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="caac70034-cit-0042"><string-name name-style="western"><surname>Yen</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>MI</given-names></string-name>, et&#160;al. <article-title>Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ</article-title>. <source>J Am Coll Surg</source>. <year>2005</year>;<volume>200</volume>(<issue>4</issue>):<fpage>516</fpage>&#8208;<lpage>526</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2004.11.012</pub-id><pub-id pub-id-type="pmid">15804465</pub-id></mixed-citation></ref><ref id="caac70034-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="caac70034-cit-0043"><string-name name-style="western"><surname>Francis</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Haugen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Grimes</surname><given-names>LM</given-names></string-name>, et&#160;al. <article-title>Is sentinel lymph node dissection warranted for patients with a diagnosis of ductal carcinoma in situ?</article-title><source>Ann Surg Oncol</source>. <year>2015</year>;<volume>22</volume>(<issue>13</issue>):<fpage>4270</fpage>&#8208;<lpage>4279</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-015-4547-7</pub-id><pub-id pub-id-type="pmid">25905585</pub-id><pub-id pub-id-type="pmcid">PMC5271669</pub-id></mixed-citation></ref><ref id="caac70034-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="caac70034-cit-0044"><string-name name-style="western"><surname>Bae</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kook</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>JS</given-names></string-name>, et&#160;al. <article-title>Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates</article-title>. <source>Breast Cancer Res</source>. <year>2024</year>;<volume>26</volume>(<issue>1</issue>):<fpage>65</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13058-024-01816-7</pub-id><pub-id pub-id-type="pmid">38609935</pub-id><pub-id pub-id-type="pmcid">PMC11015583</pub-id></mixed-citation></ref><ref id="caac70034-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="caac70034-cit-0045"><string-name name-style="western"><surname>Miller&#8208;Ocuin</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Howard&#8208;McNatt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Chiba</surname><given-names>A</given-names></string-name>. <article-title>Is sentinel lymph node biopsy necessary for ductal carcinoma in situ patients undergoing mastectomy?</article-title><source>Am Surg</source>. <year>2020</year>;<volume>86</volume>(<issue>8</issue>):<fpage>955</fpage>&#8208;<lpage>957</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0003134820942164</pub-id><pub-id pub-id-type="pmid">32862671</pub-id></mixed-citation></ref><ref id="caac70034-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="caac70034-cit-0046"><string-name name-style="western"><surname>Price</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schnabel</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chun</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS)</article-title>. <source>Breast J</source>. <year>2020</year>;<volume>26</volume>(<issue>5</issue>):<fpage>931</fpage>&#8208;<lpage>936</lpage>. doi:<pub-id pub-id-type="doi">10.1111/tbj.13737</pub-id><pub-id pub-id-type="pmid">31957944</pub-id></mixed-citation></ref><ref id="caac70034-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="caac70034-cit-0047"><string-name name-style="western"><surname>Shin</surname><given-names>YD</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></string-name>. <article-title>Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis</article-title>. <source>BMC Surg</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>159</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12893-021-01170-x</pub-id><pub-id pub-id-type="pmid">33752671</pub-id><pub-id pub-id-type="pmcid">PMC7986566</pub-id></mixed-citation></ref><ref id="caac70034-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="caac70034-cit-0048"><string-name name-style="western"><surname>Galimberti</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname><given-names>BF</given-names></string-name>, <string-name name-style="western"><surname>Viale</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel&#8208;node micrometastases (IBCSG 23&#8208;01): 10&#8208;year follow&#8208;up of a randomised, controlled phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2018</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1385</fpage>&#8208;<lpage>1393</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1470-2045(18)30380-2</pub-id><pub-id pub-id-type="pmid">30196031</pub-id></mixed-citation></ref><ref id="caac70034-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="caac70034-cit-0049"><string-name name-style="western"><surname>Verbelen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tjalma</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Meirte</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gebruers</surname><given-names>N</given-names></string-name>. <article-title>Long&#8208;term morbidity after a negative sentinel node in breast cancer patients</article-title>. <source>Eur J Cancer Care</source>. <year>2019</year>;<volume>28</volume>(<issue>5</issue>):<elocation-id>e13077</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/ecc.13077</pub-id><pub-id pub-id-type="pmid">31050088</pub-id></mixed-citation></ref><ref id="caac70034-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="caac70034-cit-0050"><string-name name-style="western"><surname>Mansel</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Fallowfield</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kissin</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial</article-title>. <source>J Natl Cancer Inst</source>. <year>2006</year>;<volume>98</volume>(<issue>9</issue>):<fpage>599</fpage>&#8208;<lpage>609</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djj158</pub-id><pub-id pub-id-type="pmid">16670385</pub-id></mixed-citation></ref><ref id="caac70034-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="caac70034-cit-0051"><string-name name-style="western"><surname>Ashikaga</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Krag</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Land</surname><given-names>SR</given-names></string-name>, et&#160;al. <article-title>Morbidity results from the NSABP B&#8208;32 trial comparing sentinel lymph node dissection versus axillary dissection</article-title>. <source>J Surg Oncol</source>. <year>2010</year>;<volume>102</volume>(<issue>2</issue>):<fpage>111</fpage>&#8208;<lpage>118</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jso.21535</pub-id><pub-id pub-id-type="pmid">20648579</pub-id><pub-id pub-id-type="pmcid">PMC3072246</pub-id></mixed-citation></ref><ref id="caac70034-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="caac70034-cit-0052"><string-name name-style="western"><surname>Killelea</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Dang</surname><given-names>W</given-names></string-name>, et al. <article-title>Associations between sentinel lymph node biopsy and complications for patients with ductal carcinoma in situ</article-title>. <source>Ann Surg Oncol</source>. <year>2018</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1521</fpage>&#8208;<lpage>1529</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-018-6410-0</pub-id><pub-id pub-id-type="pmid">29516364</pub-id><pub-id pub-id-type="pmcid">PMC5928184</pub-id></mixed-citation></ref><ref id="caac70034-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="caac70034-cit-0053"><string-name name-style="western"><surname>Alvarado</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Mittendorf</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Teshome</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>SentimagIC: a non&#8208;inferiority trial comparing superparamagnetic iron oxide versus technetium&#8208;99m and blue dye in the detection of axillary sentinel nodes in patients with early&#8208;stage breast cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2019</year>;<volume>26</volume>(<issue>11</issue>):<fpage>3510</fpage>&#8208;<lpage>3516</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-019-07577-4</pub-id><pub-id pub-id-type="pmid">31297674</pub-id></mixed-citation></ref><ref id="caac70034-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="caac70034-cit-0054"><string-name name-style="western"><surname>Karakatsanis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Christiansen</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta&#8208;analysis of earlier studies</article-title>. <source>Breast Cancer Res Treat</source>. <year>2016</year>;<volume>157</volume>(<issue>2</issue>):<fpage>281</fpage>&#8208;<lpage>294</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-016-3809-9</pub-id><pub-id pub-id-type="pmid">27117158</pub-id><pub-id pub-id-type="pmcid">PMC4875068</pub-id></mixed-citation></ref><ref id="caac70034-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="caac70034-cit-0055"><string-name name-style="western"><surname>Teshome</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mittendorf</surname><given-names>EA</given-names></string-name>. <article-title>Use of a magnetic tracer for sentinel lymph node detection in early&#8208;stage breast cancer patients: a meta&#8208;analysis</article-title>. <source>Ann Surg Oncol</source>. <year>2016</year>;<volume>23</volume>(<issue>5</issue>):<fpage>1508</fpage>&#8208;<lpage>1514</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-016-5135-1</pub-id><pub-id pub-id-type="pmid">26893221</pub-id></mixed-citation></ref><ref id="caac70034-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="caac70034-cit-0056"><string-name name-style="western"><surname>Karakatsanis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eriksson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pistiolis</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: the SentiNot Study</article-title>. <source>Ann Surg Oncol</source>. <year>2023</year>;<volume>30</volume>(<issue>7</issue>):<fpage>4064</fpage>&#8208;<lpage>4072</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-022-13064-0</pub-id><pub-id pub-id-type="pmid">36719570</pub-id><pub-id pub-id-type="pmcid">PMC10250503</pub-id></mixed-citation></ref><ref id="caac70034-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="caac70034-cit-0057"><string-name name-style="western"><surname>Addae</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Sweeting</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Meszoely</surname><given-names>IM</given-names></string-name>, et&#160;al. <article-title>Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single&#8208;institution experience</article-title>. <source>Breast Cancer Res Treat</source>. <year>2024</year>;<volume>204</volume>(<issue>1</issue>):<fpage>117</fpage>&#8208;<lpage>121</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-023-07193-7</pub-id><pub-id pub-id-type="pmid">38087058</pub-id></mixed-citation></ref><ref id="caac70034-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="caac70034-cit-0058"><string-name name-style="western"><surname>Cui</surname><given-names>RBJ</given-names></string-name>, <string-name name-style="western"><surname>Hawes</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Azimi</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Avoiding unnecessary sentinel lymph node biopsy with the use of superparamagnetic iron oxide mapping agents (Magtrace&#174;) in breast surgery</article-title>. <source>ANZ J Surg</source>. <year>2024</year>;<volume>94</volume>(<issue>6</issue>):<fpage>1090</fpage>&#8208;<lpage>1095</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ans.18936</pub-id><pub-id pub-id-type="pmid">38456358</pub-id></mixed-citation></ref><ref id="caac70034-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="caac70034-cit-0059"><string-name name-style="western"><surname>Samaha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fellner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Raque</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kuritzky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wexelman</surname><given-names>B</given-names></string-name>. <article-title>Magnetic lymphatic tracing for omission of sentinel lymph node biopsies in mastectomy patients: a community cancer center experience</article-title>. <source>Breast Cancer Res Treat</source>. <year>2024</year>;<volume>209</volume>(<issue>1</issue>):<fpage>161</fpage>&#8208;<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-024-07482-9</pub-id><pub-id pub-id-type="pmid">39316204</pub-id></mixed-citation></ref><ref id="caac70034-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="caac70034-cit-0060"><string-name name-style="western"><surname>Cuzick</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sestak</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Pinder</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long&#8208;term results from the UK/ANZ DCIS trial</article-title>. <source>Lancet Oncol</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>21</fpage>&#8208;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1470-2045(10)70266-7</pub-id><pub-id pub-id-type="pmid">21145284</pub-id><pub-id pub-id-type="pmcid">PMC3018565</pub-id></mixed-citation></ref><ref id="caac70034-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="caac70034-cit-0061"><string-name name-style="western"><surname>Fisher</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dignam</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wolmark</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B&#8208;17</article-title>. <source>J Clin Oncol</source>. <year>1998</year>;<volume>16</volume>(<issue>2</issue>):<fpage>441</fpage>&#8208;<lpage>452</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.1998.16.2.441</pub-id><pub-id pub-id-type="pmid">9469327</pub-id></mixed-citation></ref><ref id="caac70034-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="caac70034-cit-0062"><collab collab-type="authors">EORTC Breast Cancer Cooperative Group</collab>
; <string-name name-style="western"><surname>Meijnen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Peterse</surname><given-names>JL</given-names></string-name>, et&#160;al. <article-title>Breast&#8208;conserving treatment with or without radiotherapy in ductal carcinoma&#8208;in&#8208;situ: ten&#8208;year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853&#8212;a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group</article-title>. <source>J Clin Oncol</source>. <year>2006</year>;<volume>24</volume>(<issue>21</issue>):<fpage>3381</fpage>&#8208;<lpage>3387</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2006.06.1366</pub-id><pub-id pub-id-type="pmid">16801628</pub-id></mixed-citation></ref><ref id="caac70034-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="caac70034-cit-0063"><string-name name-style="western"><surname>Holmberg</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Garmo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Granstrand</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1247</fpage>&#8208;<lpage>1252</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2007.12.7969</pub-id><pub-id pub-id-type="pmid">18250350</pub-id></mixed-citation></ref><ref id="caac70034-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="caac70034-cit-0064"><string-name name-style="western"><surname>Hong</surname><given-names>YK</given-names></string-name>, <string-name name-style="western"><surname>McMasters</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Ajkay</surname><given-names>N</given-names></string-name>. <article-title>Ductal carcinoma in situ current trends, controversies, and review of literature</article-title>. <source>Am J Surg</source>. <year>2018</year>;<volume>216</volume>(<issue>5</issue>):<fpage>998</fpage>&#8208;<lpage>1003</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjsurg.2018.06.013</pub-id><pub-id pub-id-type="pmid">30244816</pub-id></mixed-citation></ref><ref id="caac70034-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="caac70034-cit-0065"><string-name name-style="western"><surname>Delaloge</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Wesseling</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Whelan</surname><given-names>T</given-names></string-name>. <article-title>Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment</article-title>. <source>Lancet</source>. <year>2024</year>;<volume>403</volume>(<issue>10445</issue>):<fpage>2734</fpage>&#8208;<lpage>2746</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(24)00425-2</pub-id><pub-id pub-id-type="pmid">38735296</pub-id></mixed-citation></ref><ref id="caac70034-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="caac70034-cit-0066"><string-name name-style="western"><surname>Hendrickson</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kohlmann</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Radiation therapy and secondary malignancy in Li&#8211;Fraumeni syndrome: a hereditary cancer registry study</article-title>. <source>Cancer Med</source>. <year>2020</year>;<volume>9</volume>(<issue>21</issue>):<fpage>7954</fpage>&#8208;<lpage>7963</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.3427</pub-id><pub-id pub-id-type="pmid">32931654</pub-id><pub-id pub-id-type="pmcid">PMC7643676</pub-id></mixed-citation></ref><ref id="caac70034-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="caac70034-cit-0067"><string-name name-style="western"><surname>Heymann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Delaloge</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rahal</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Radio&#8208;induced malignancies after breast cancer postoperative radiotherapy in patients with Li&#8211;Fraumeni syndrome</article-title>. <source>Radiat Oncol</source>. <year>2010</year>;<volume>5</volume>(<issue>1</issue>):<elocation-id>104</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/1748-717x-5-104</pub-id><pub-id pub-id-type="pmid">21059199</pub-id><pub-id pub-id-type="pmcid">PMC2988810</pub-id></mixed-citation></ref><ref id="caac70034-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="caac70034-cit-0068"><string-name name-style="western"><surname>Petry</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bonadio</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Moutinho</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Frequency of radiation therapy&#8208;induced malignancies in patients with Li&#8211;Fraumeni syndrome and early&#8208;stage breast cancer and the influence of radiation therapy technique</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2024</year>;<volume>119</volume>(<issue>4</issue>):<fpage>1086</fpage>&#8208;<lpage>1091</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijrobp.2024.01.204</pub-id><pub-id pub-id-type="pmid">38309330</pub-id></mixed-citation></ref><ref id="caac70034-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="caac70034-cit-0069"><string-name name-style="western"><surname>Farante</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Toesca</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Magnoni</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Advances and controversies in management of breast ductal carcinoma in situ (DCIS)</article-title>. <source>Eur J Surg Oncol</source>. <year>2022</year>;<volume>48</volume>(<issue>4</issue>):<fpage>736</fpage>&#8208;<lpage>741</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejso.2021.10.030</pub-id><pub-id pub-id-type="pmid">34772587</pub-id></mixed-citation></ref><ref id="caac70034-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="caac70034-cit-0070"><string-name name-style="western"><surname>Hophan</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Odnokoz</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Ductal carcinoma in situ of breast: from molecular etiology to therapeutic management</article-title>. <source>Endocrinology</source>. <year>2022</year>;<volume>163</volume>(<issue>4</issue>):<elocation-id>bqac027</elocation-id>. doi:<pub-id pub-id-type="doi">10.1210/endocr/bqac027</pub-id><pub-id pub-id-type="pmid">35245349</pub-id><pub-id pub-id-type="pmcid">PMC8962444</pub-id></mixed-citation></ref><ref id="caac70034-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="caac70034-cit-0071"><string-name name-style="western"><surname>Wilson</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Dinh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pathmanathan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>JD</given-names></string-name>. <article-title>Ductal carcinoma in situ: molecular changes accompanying disease progression</article-title>. <source>J Mammary Gland Biol Neoplasia</source>. <year>2022</year>;<volume>27</volume>(<issue>1</issue>):<fpage>101</fpage>&#8208;<lpage>131</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10911-022-09517-7</pub-id><pub-id pub-id-type="pmid">35567670</pub-id><pub-id pub-id-type="pmcid">PMC9135892</pub-id></mixed-citation></ref><ref id="caac70034-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="caac70034-cit-0072"><string-name name-style="western"><surname>Allred</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Paik</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor&#8208;positive ductal carcinoma in situ: a study based on NSABP protocol B&#8208;24</article-title>. <source>J Clin Oncol</source>. <year>2012</year>;<volume>30</volume>(<issue>12</issue>):<fpage>1268</fpage>&#8208;<lpage>1273</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2010.34.0141</pub-id><pub-id pub-id-type="pmid">22393101</pub-id><pub-id pub-id-type="pmcid">PMC3341142</pub-id></mixed-citation></ref><ref id="caac70034-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="caac70034-cit-0073"><string-name name-style="western"><surname>Mannu</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Broggio</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988&#8211;2014: population based observational cohort study</article-title>. <source>BMJ</source>. <year>2020</year>;<volume>369</volume>:<elocation-id>m1570</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmj.m1570</pub-id><pub-id pub-id-type="pmid">32461218</pub-id><pub-id pub-id-type="pmcid">PMC7251423</pub-id></mixed-citation></ref><ref id="caac70034-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="caac70034-cit-0074"><string-name name-style="western"><surname>Simpson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dietz</surname><given-names>J</given-names></string-name>. <article-title>Diagnosis and management of phyllodes tumors of the breast</article-title>. <source>Ann Breast Surg</source>. <year>2021</year>;<volume>5</volume>:<fpage>8</fpage>. doi:<pub-id pub-id-type="doi">10.21037/abs-20-99</pub-id></mixed-citation></ref><ref id="caac70034-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="caac70034-cit-0075"><string-name name-style="western"><surname>Bogach</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shakeel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>NJL</given-names></string-name>. <article-title>Phyllodes tumors: a scoping review of the literature</article-title>. <source>Ann Surg Oncol</source>. <year>2022</year>;<volume>29</volume>(<issue>1</issue>):<fpage>446</fpage>&#8208;<lpage>459</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-021-10468-2</pub-id><pub-id pub-id-type="pmid">34296360</pub-id></mixed-citation></ref><ref id="caac70034-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="caac70034-cit-0076"><string-name name-style="western"><surname>Barth</surname><given-names>RJ</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Wells</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname><given-names>BF</given-names></string-name>. <article-title>A prospective, multi&#8208;institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors</article-title>. <source>Ann Surg Oncol</source>. <year>2009</year>;<volume>16</volume>(<issue>8</issue>):<fpage>2288</fpage>&#8208;<lpage>2294</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-009-0489-2</pub-id><pub-id pub-id-type="pmid">19424757</pub-id><pub-id pub-id-type="pmcid">PMC5053421</pub-id></mixed-citation></ref><ref id="caac70034-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="caac70034-cit-0077"><string-name name-style="western"><surname>Gnerlich</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jaskowiak</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kulkarni</surname><given-names>SA</given-names></string-name>. <article-title>Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998&#8211;2009</article-title>. <source>Ann Surg Oncol</source>. <year>2014</year>;<volume>21</volume>(<issue>4</issue>):<fpage>1222</fpage>&#8208;<lpage>1230</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-013-3395-6</pub-id><pub-id pub-id-type="pmid">24306659</pub-id></mixed-citation></ref><ref id="caac70034-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="caac70034-cit-0078"><string-name name-style="western"><surname>Chao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta&#8208;analysis</article-title>. <source>BMC Cancer</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>372</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-019-5585-5</pub-id><pub-id pub-id-type="pmid">31014268</pub-id><pub-id pub-id-type="pmcid">PMC6480723</pub-id></mixed-citation></ref><ref id="caac70034-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="caac70034-cit-0079"><string-name name-style="western"><surname>Goodwin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Oyinlola</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Palhang</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Metastatic and malignant phyllodes tumors of the breast: an update for current management</article-title>. <source>Am Surg</source>. <year>2023</year>;<volume>89</volume>(<issue>12</issue>):<fpage>6190</fpage>&#8208;<lpage>6196</lpage>. doi:<pub-id pub-id-type="doi">10.1177/00031348231198114</pub-id><pub-id pub-id-type="pmid">37611540</pub-id></mixed-citation></ref><ref id="caac70034-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="caac70034-cit-0080"><string-name name-style="western"><surname>Rosenberger</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Nimbkar</surname><given-names>SN</given-names></string-name>, et&#160;al. <article-title>Germline genetic mutations in a multi&#8208;center contemporary cohort of 550 phyllodes tumors: an opportunity for expanded multi&#8208;gene panel testing</article-title>. <source>Ann Surg Oncol</source>. <year>2020</year>;<volume>27</volume>(<issue>10</issue>):<fpage>3633</fpage>&#8208;<lpage>3640</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-020-08480-z</pub-id><pub-id pub-id-type="pmid">32504368</pub-id><pub-id pub-id-type="pmcid">PMC9945652</pub-id></mixed-citation></ref><ref id="caac70034-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="caac70034-cit-0081"><string-name name-style="western"><surname>Kratz</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Achatz</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Brugi&#232;res</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Cancer screening recommendations for individuals with Li&#8211;Fraumeni syndrome</article-title>. <source>Clin Cancer Res</source>. <year>2017</year>;<volume>23</volume>(<issue>11</issue>):<fpage>e38</fpage>&#8208;<lpage>e45</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.ccr-17-0408</pub-id><pub-id pub-id-type="pmid">28572266</pub-id></mixed-citation></ref><ref id="caac70034-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="caac70034-cit-0082"><string-name name-style="western"><surname>Kumar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Phelps</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tulpule</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Matthay</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nicolaides</surname><given-names>T</given-names></string-name>. <article-title>Surveillance screening in Li&#8211;Fraumeni syndrome: raising awareness of false positives</article-title>. <source>Cureus</source>. <year>2018</year>;<volume>10</volume>(<issue>4</issue>):<elocation-id>e2527</elocation-id>. doi:<pub-id pub-id-type="doi">10.7759/cureus.2527</pub-id><pub-id pub-id-type="pmid">29946497</pub-id><pub-id pub-id-type="pmcid">PMC6017131</pub-id></mixed-citation></ref><ref id="caac70034-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="caac70034-cit-0083"><string-name name-style="western"><surname>Ballinger</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Best</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>PL</given-names></string-name>, et&#160;al. <article-title>Baseline surveillance in Li&#8211;Fraumeni syndrome using whole&#8208;body magnetic resonance imaging: a meta&#8208;analysis</article-title>. <source>JAMA Oncol</source>. <year>2017</year>;<volume>3</volume>(<issue>12</issue>):<fpage>1634</fpage>&#8208;<lpage>1639</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2017.1968</pub-id><pub-id pub-id-type="pmid">28772291</pub-id><pub-id pub-id-type="pmcid">PMC5824277</pub-id></mixed-citation></ref><ref id="caac70034-bib-0084"><label>84</label><mixed-citation publication-type="book" id="caac70034-cit-0084"><collab collab-type="authors">National Comprehensive Cancer Network&#174; (NCCN&#174;)</collab>
. <source>Genetic/Familial High&#8208;Risk Assessment: Colorectal, Endometrial, and Gastric. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) Version 2.2024</source>. <publisher-name>NCCN</publisher-name>; <year>2024</year>. Accessed October 22, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=2%26id=1544" ext-link-type="uri">https://www.nccn.org/guidelines/guidelines&#8208;detail?category=2&amp;id=1544</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2024.0061</pub-id><pub-id pub-id-type="pmid">39689429</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>